{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:23:30Z","timestamp":1789770210396,"version":"4.0.1"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,7,26]],"date-time":"2013-07-26T00:00:00Z","timestamp":1374796800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1007\/s11886-013-0397-8","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T16:45:07Z","timestamp":1374770707000},"source":"Crossref","is-referenced-by-count":34,"title":["Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy"],"prefix":"10.1007","volume":"15","author":[{"given":"Olov","family":"Wiklund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pirazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,7,26]]},"reference":[{"key":"397_CR1","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1365-2796.2010.02339.x","volume":"269","author":"L Bjorck","year":"2011","unstructured":"Bjorck L, Capewell S, Bennett K, Lappas G, Rosengren A. Increasing evidence-based treatments to reduce coronary heart disease mortality in Sweden: quantifying the potential gains. J Intern Med. 2011;269:452\u201367.","journal-title":"J Intern Med"},{"key":"397_CR2","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/eurheartj\/ehn554","volume":"30","author":"L Bjorck","year":"2009","unstructured":"Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J. 2009;30:1046\u201356.","journal-title":"Eur Heart J"},{"key":"397_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","volume":"217","author":"AL Catapano","year":"2011","unstructured":"\u2022 Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC\/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:3\u201346. These European guidelines give an updated information about the background and the treatment of dyslipidaemias in cardiovascular prevention.","journal-title":"Atherosclerosis"},{"key":"397_CR4","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"J Perk","year":"2012","unstructured":"Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 9 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33:1635\u2013701.","journal-title":"Eur Heart J"},{"key":"397_CR5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","volume":"32","author":"MJ Chapman","year":"2011","unstructured":"Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32:1345\u201361.","journal-title":"Eur Heart J"},{"key":"397_CR6","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/S0140-6736(01)07098-2","volume":"358","author":"G Walldius","year":"2001","unstructured":"Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026\u201333.","journal-title":"Lancet"},{"key":"397_CR7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2796.2010.02277.x","volume":"268","author":"S Holewijn","year":"2010","unstructured":"Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med. 2010;268:567\u201377.","journal-title":"J Intern Med"},{"key":"397_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4:337\u201345.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"397_CR9","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Angelantonio Di","year":"2009","unstructured":"Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993\u20132000.","journal-title":"JAMA"},{"key":"397_CR10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1001\/jama.2012.6571","volume":"307","author":"E Angelantonio Di","year":"2012","unstructured":"\u2022\u2022 Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, et al. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499\u2013506. An important analysis of the effects on risk prediction when cholesterol based lipid markers are substituted by emerging measures, or new markers are added.","journal-title":"JAMA"},{"key":"397_CR11","doi-asserted-by":"crossref","first-page":"e40878","DOI":"10.1371\/journal.pone.0040878","volume":"7","author":"G Tognon","year":"2012","unstructured":"Tognon G, Berg C, Mehlig K, Thelle D, Strandhagen E, Gustavsson J, et al. Comparison of apolipoprotein (apoB\/apoA-I) and lipoprotein (total cholesterol\/HDL) ratio determinants. Focus on obesity, diet, and alcohol intake. PLoS One. 2012;7:e40878.","journal-title":"PLoS One"},{"key":"397_CR12","doi-asserted-by":"crossref","unstructured":"Ndumele CE, Matsushita K, Astor B, Virani SS, Mora S, Williams EK, et al. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: The ARIC Study. Eur J Prev Cardiol. 2012. doi: 10.1177\/2047487312465523 .","DOI":"10.1177\/2047487312465523"},{"key":"397_CR13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11883-011-0224-x","volume":"14","author":"JS Rana","year":"2012","unstructured":"Rana JS, Boekholdt SM, Kastelein JJ, Shah PK. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr Atheroscler Rep. 2012;14:130\u20134.","journal-title":"Curr Atheroscler Rep"},{"key":"397_CR14","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375:1634\u20139.","journal-title":"Lancet"},{"key":"397_CR15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","volume":"20","author":"N Ewald","year":"2009","unstructured":"Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol. 2009;20:497\u2013504.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/01.mol.0000236367.42755.c1","volume":"17","author":"CJ Packard","year":"2006","unstructured":"Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006;17:412\u20137.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR17","doi-asserted-by":"crossref","unstructured":"Kamstrup PR, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146\u201356.","DOI":"10.1016\/j.jacc.2012.12.023"},{"key":"397_CR18","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844\u201353.","journal-title":"Eur Heart J"},{"key":"397_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","volume":"273","author":"F Kronenberg","year":"2013","unstructured":"Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med. 2013;273:6\u201330.","journal-title":"J Intern Med"},{"key":"397_CR20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/1354750X.2012.664170","volume":"17","author":"O Vittos","year":"2012","unstructured":"Vittos O, Toana B, Vittos A, Moldoveanu E. Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers. 2012;17:289\u2013302.","journal-title":"Biomarkers"},{"key":"397_CR21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/MOL.0b013e328351b439","volume":"23","author":"DY Hui","year":"2012","unstructured":"Hui DY. Phospholipase A(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol. 2012;23:235\u201340.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2011.06.012","volume":"217","author":"AL Catapano","year":"2011","unstructured":"Catapano AL, Chapman J, Wiklund O, Taskinen MR. The new joint EAS\/ESC guidelines for the management of dyslipidaemias. Atherosclerosis. 2011;217:1.","journal-title":"Atherosclerosis"},{"key":"397_CR23","doi-asserted-by":"crossref","unstructured":"Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143\u2013421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"397_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227\u201339.","journal-title":"Circulation"},{"key":"397_CR25","doi-asserted-by":"crossref","unstructured":"JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005;91(Suppl 5):v1\u201352.","DOI":"10.1136\/hrt.2005.079988"},{"key":"397_CR26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","volume":"25","author":"J Genest","year":"2009","unstructured":"Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009;25:567\u201379.","journal-title":"Can J Cardiol"},{"key":"397_CR27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)62027-3","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"\u2022\u2022 Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581\u201390. An important meta-analysis showing effects of statin treatment also in patient with low risk.","journal-title":"Lancet"},{"key":"397_CR28","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"397_CR29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jacl.2012.05.004","volume":"6","author":"A Sniderman","year":"2012","unstructured":"Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012;6:303\u20139.","journal-title":"J Clin Lipidol"},{"key":"397_CR30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/HCO.0b013e328353fed5","volume":"27","author":"AD Sniderman","year":"2012","unstructured":"Sniderman AD, De Graaf J, Couture P. Low-density lipoprotein-lowering strategies: target versus maximalist versus population percentile. Curr Opin Cardiol. 2012;27:405\u201311.","journal-title":"Curr Opin Cardiol"},{"key":"397_CR31","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","volume":"110","author":"JG Robinson","year":"2012","unstructured":"Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am J Cardiol. 2012;110:1468\u201376.","journal-title":"Am J Cardiol"},{"key":"397_CR32","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1161\/CIRCULATIONAHA.111.088591","volume":"125","author":"S Mora","year":"2012","unstructured":"Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012;125:1979\u201387.","journal-title":"Circulation"},{"key":"397_CR33","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302\u20139.","journal-title":"JAMA"},{"key":"397_CR34","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2011.12.035","volume":"59","author":"S Mora","year":"2012","unstructured":"Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJ, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012;59:1521\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"397_CR35","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109\u201322.","journal-title":"N Engl J Med"},{"key":"397_CR36","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089\u201399.","journal-title":"N Engl J Med"},{"key":"397_CR37","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572\u201380.","journal-title":"Lancet"},{"key":"397_CR38","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","volume":"35","author":"TC Weng","year":"2010","unstructured":"Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35:139\u201351.","journal-title":"J Clin Pharm Ther"},{"key":"397_CR39","first-page":"415","volume":"8","author":"BA Phan","year":"2012","unstructured":"Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415\u201327.","journal-title":"Vasc Health Risk Manag"},{"key":"397_CR40","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S1734-1140(11)70698-3","volume":"63","author":"D Suchy","year":"2011","unstructured":"Suchy D, Labuzek K, Stadnicki A, Okopien B. Ezetimibe\u2013a new approach in hypercholesterolemia management. Pharmacol Rep. 2011;63:1335\u201348.","journal-title":"Pharmacol Rep"},{"key":"397_CR41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.atherosclerosis.2011.06.010","volume":"217","author":"OS Descamps","year":"2011","unstructured":"Descamps OS, De Sutter J, Guillaume M, Missault L. Where does the interplay between cholesterol absorption and synthesis in the context of statin and\/or ezetimibe treatment stand today? Atherosclerosis. 2011;217:308\u201321.","journal-title":"Atherosclerosis"},{"key":"397_CR42","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","volume":"156","author":"CP Cannon","year":"2008","unstructured":"Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826\u201332.","journal-title":"Am Heart J"},{"key":"397_CR43","doi-asserted-by":"crossref","first-page":"14C","DOI":"10.1016\/0002-9149(84)90851-8","volume":"54","author":"HA Tyroler","year":"1984","unstructured":"Tyroler HA. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol. 1984;54:14C\u20139C.","journal-title":"Am J Cardiol"},{"key":"397_CR44","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","volume":"126","author":"MJ Chapman","year":"2010","unstructured":"Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126:314\u201345.","journal-title":"Pharmacol Ther"},{"key":"397_CR45","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"397_CR46","doi-asserted-by":"crossref","unstructured":"Group H-TC. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279\u201391.","DOI":"10.1093\/eurheartj\/eht055"},{"key":"397_CR47","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0b013e328338ca61","volume":"21","author":"S Romeo","year":"2010","unstructured":"Romeo S, Huang-Doran I, Baroni MG, Kotronen A. Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr Opin Lipidol. 2010;21:247\u201352.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR48","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"397_CR49","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.amjmed.2008.02.031","volume":"121","author":"GO Coodley","year":"2008","unstructured":"Coodley GO, Jorgensen M, Kirschenbaum J, Sparks C, Zeigler L, Albertson BD. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative. Am J Med. 2008;121:604\u201310.","journal-title":"Am J Med"},{"key":"397_CR50","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0009-9120(99)00030-2","volume":"32","author":"DJ Nazir","year":"1999","unstructured":"Nazir DJ, Roberts RS, Hill SA, McQueen MJ. Monthly intra-individual variation in lipids over a 1-year period in 22 normal subjects. Clin Biochem. 1999;32:381\u20139.","journal-title":"Clin Biochem"},{"key":"397_CR51","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.164.8.863","volume":"164","author":"IS Ockene","year":"2004","unstructured":"Ockene IS, Chiriboga DE, Stanek III EJ, Harmatz MG, Nicolosi R, Saperia G, et al. Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms. Arch Intern Med. 2004;164:863\u201370.","journal-title":"Arch Intern Med"},{"key":"397_CR52","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","volume":"40","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith Jr SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"397_CR53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","volume":"10","author":"TT Abd","year":"2011","unstructured":"\u2022 Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10:373\u201387. This review and update summarizes the most recent studies on statins and myopathy.","journal-title":"Expert Opin Drug Saf"},{"key":"397_CR54","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97:52C\u201360C.","journal-title":"Am J Cardiol"},{"key":"397_CR55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","volume":"28","author":"MA Silva","year":"2006","unstructured":"Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28:26\u201335.","journal-title":"Clin Ther"},{"key":"397_CR56","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","volume":"97","author":"MH Davidson","year":"2006","unstructured":"Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006;97:32C\u201343C.","journal-title":"Am J Cardiol"},{"key":"397_CR57","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"397_CR58","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DMSO.S11244","volume":"4","author":"M Arca","year":"2011","unstructured":"Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes. 2011;4:155\u201366.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"397_CR59","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","volume":"114","author":"A Kashani","year":"2006","unstructured":"Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788\u201397.","journal-title":"Circulation"},{"key":"397_CR60","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","volume":"29","author":"M Silva","year":"2007","unstructured":"Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253\u201360.","journal-title":"Clin Ther"},{"key":"397_CR61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMp1106689","volume":"365","author":"A Egan","year":"2011","unstructured":"Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med. 2011;365:285\u20137.","journal-title":"N Engl J Med"},{"key":"397_CR62","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","volume":"24","author":"S Denus de","year":"2004","unstructured":"de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy. 2004;24:584\u201391.","journal-title":"Pharmacotherapy"},{"key":"397_CR63","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.amjcard.2008.08.014","volume":"102","author":"J Wlodarczyk","year":"2008","unstructured":"Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol. 2008;102:1654\u201362.","journal-title":"Am J Cardiol"},{"key":"397_CR64","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","volume":"74","author":"RH Bradford","year":"1994","unstructured":"Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: 2-year efficacy and safety follow-up. Am J Cardiol. 1994;74:667\u201373.","journal-title":"Am J Cardiol"},{"key":"397_CR65","doi-asserted-by":"crossref","first-page":"77C","DOI":"10.1016\/j.amjcard.2005.12.014","volume":"97","author":"DE Cohen","year":"2006","unstructured":"Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97:77C\u201381C.","journal-title":"Am J Cardiol"},{"key":"397_CR66","doi-asserted-by":"crossref","first-page":"89C","DOI":"10.1016\/j.amjcard.2006.02.030","volume":"97","author":"JM McKenney","year":"2006","unstructured":"McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C\u201394C.","journal-title":"Am J Cardiol"},{"key":"397_CR67","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2012.05.002","volume":"10","author":"ZA Marcum","year":"2012","unstructured":"Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012;10:264\u201371.","journal-title":"Am J Geriatr Pharmacother"},{"key":"397_CR68","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","volume":"329","author":"R Vuppalanchi","year":"2005","unstructured":"Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci. 2005;329:62\u20135.","journal-title":"Am J Med Sci"},{"key":"397_CR69","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","volume":"126","author":"N Chalasani","year":"2004","unstructured":"Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287\u201392.","journal-title":"Gastroenterology"},{"key":"397_CR70","first-page":"711","volume":"83","author":"RC Gillett Jr","year":"2011","unstructured":"Gillett Jr RC, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicitiy. Am Fam Physician. 2011;83:711\u20136.","journal-title":"Am Fam Physician"},{"key":"397_CR71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","volume":"174","author":"LS Rallidis","year":"2004","unstructured":"Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004;174:193\u20136.","journal-title":"Atherosclerosis"},{"key":"397_CR72","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jacl.2012.01.009","volume":"6","author":"KH Han","year":"2012","unstructured":"Han KH, Rha SW, Kang HJ, Bae JW, Choi BJ, Choi SY, et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol. 2012;6:340\u201351.","journal-title":"J Clin Lipidol"},{"key":"397_CR73","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10620-012-2118-3","volume":"57","author":"W Nseir","year":"2012","unstructured":"Nseir W, Mograbi J, Ghali M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci. 2012;57:1773\u201381.","journal-title":"Dig Dis Sci"},{"key":"397_CR74","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MOL.0b013e3283541cfc","volume":"23","author":"AS Wierzbicki","year":"2012","unstructured":"Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol. 2012;23:345\u201352.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR75","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","volume":"375","author":"N Sattar","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735\u201342.","journal-title":"Lancet"},{"key":"397_CR76","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.2337\/dc09-0738","volume":"32","author":"SN Rajpathak","year":"2009","unstructured":"Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924\u20139.","journal-title":"Diabetes Care"},{"key":"397_CR77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MOL.0b013e32834b4994","volume":"22","author":"D Preiss","year":"2011","unstructured":"Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011;22:460\u20136.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2013.02.015","volume":"61","author":"DD Waters","year":"2013","unstructured":"Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61:148\u201352.","journal-title":"J Am Coll Cardiol"},{"key":"397_CR79","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/CIRCULATIONAHA.112.122135","volume":"126","author":"RV Shah","year":"2012","unstructured":"Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation. 2012;126:e282\u20134.","journal-title":"Circulation"},{"key":"397_CR80","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1056\/NEJMp1203020","volume":"366","author":"AB Goldfine","year":"2012","unstructured":"Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med. 2012;366:1752\u20135.","journal-title":"N Engl J Med"},{"key":"397_CR81","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","volume":"99","author":"MH Davidson","year":"2007","unstructured":"Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99:3C\u201318C.","journal-title":"Am J Cardiol"},{"key":"397_CR82","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOL.0b013e3282364add","volume":"18","author":"JR Guyton","year":"2007","unstructured":"Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol. 2007;18:415\u201320.","journal-title":"Curr Opin Lipidol"},{"key":"397_CR83","doi-asserted-by":"crossref","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","volume":"99","author":"JR Guyton","year":"2007","unstructured":"Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99:22C\u201331C.","journal-title":"Am J Cardiol"},{"key":"397_CR84","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","volume":"223","author":"D Morrone","year":"2012","unstructured":"Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251\u201361.","journal-title":"Atherosclerosis"},{"key":"397_CR85","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11584310-000000000-00000","volume":"10","author":"MH Davidson","year":"2010","unstructured":"Davidson MH, Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs. 2010;10:305\u201314.","journal-title":"Am J Cardiovasc Drugs"},{"key":"397_CR86","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1185\/030079908X280446","volume":"24","author":"M Florentin","year":"2008","unstructured":"Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin. 2008;24:995\u20131009.","journal-title":"Curr Med Res Opin"},{"key":"397_CR87","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jacc.2010.01.013","volume":"55","author":"K Gransbo","year":"2010","unstructured":"\u2022 Gransbo K, Melander O, Wallentin L, Lindback J, Stenestrand U, Carlsson J, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol. 2010;55:1362\u20139. This study gives unique information about outcome of the very elderly during statin treatment after myocartdial infarction.","journal-title":"J Am Coll Cardiol"},{"key":"397_CR88","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MED.0b013e3282f7cd6d","volume":"15","author":"DB Walker","year":"2008","unstructured":"Walker DB, Jacobson TA. Initiating statins in the elderly: the evolving challenge. Curr Opin Endocrinol Diabetes Obes. 2008;15:182\u20137.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"397_CR89","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","volume":"23","author":"LR Wagstaff","year":"2003","unstructured":"Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871\u201380.","journal-title":"Pharmacotherapy"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-013-0397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-013-0397-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-013-0397-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T13:17:10Z","timestamp":1563542230000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-013-0397-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,26]]},"references-count":89,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s11886-013-0397-8","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,26]]},"article-number":"397"}}